• Veradermics outlined late-stage plans for VDPHL01, an extended-release oral minoxidil tablet being developed for pattern hair loss, positioned to increase exposure for hair growth while keeping peak concentrations below cardiac activity thresholds.
• Topline data from Part A of Study 302 in males showed statistically significant gains in non-vellus target area hair count at month 6, with increases of 30.3 hairs for 8.5 mg once daily and 33.0 hairs for 8.5 mg twice daily versus 7.3 hairs for placebo.
• Confirmatory Phase 3 Study 304 in 552 males is fully enrolled, with a 6-month topline readout expected in H2 2026.
• Female program Study 306, a Phase 2/3 trial, is enrolling as company targets first FDA-approved oral option for women with pattern hair loss.
• Presentation framed commercial opportunity around 80 million US patients with pattern hair loss, with about 74 million described as addressable.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.